fig1
![The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities](https://image.oaes.cc/a506494c-1103-42df-878d-ff2cd23dbbde/cdr6008.fig.1.jpg)
Figure 1. Indirect comparison of PFS with PARPi maintenance according to BRCA or HRD/LOH status in the main randomized phase 3 trials. In VELIA trial, PFS was calculated from the start of chemotherapy. ATHENA MONO: PFS in BRCA mutated population is not reached. BRCAmut: BRCA mutated; BRCAwt: BRCA wild type; HRD: homologous recombination deficiency; HRp: homologous recombination proficiency; LOH: loss of heterozygosity; PARPi: poly (ADP-ribose) polymerase inhibitors; PFS: progression-free survival; VELIA: PSF in HRD/BRCAwt not reported.